|
| 37977486 | Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening. | J Thorac Oncol | 2024 |
| 37903180 | Novel Approach to Accelerate Lung Cancer Research: Lung-MAP and the Potential of Public-Private Partnerships. | Clin Cancer Res | 2024 |
| 36271141 | BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC. | Nat Rev Clin Oncol | 2023 |
| 37792623 | Osimertinib in Resected EGFR-Mutated NSCLC. Reply. | N Engl J Med | 2023 |
| 37677122 | Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). | JCO Precis Oncol | 2023 |
| 37024582 | Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. | Nat Genet | 2023 |
| 37024390 | Advances and Opportunities in the Management of Lung Cancer. | Hematol Oncol Clin North Am | 2023 |
| 37390374 | Reply to D. Wu et al. | J Clin Oncol | 2023 |
| 37084329 | Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG). | JCO Clin Cancer Inform | 2023 |
| 37272535 | Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLC. | N Engl J Med | 2023 |
| 37236398 | Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. | J Thorac Oncol | 2023 |
| 37429923 | Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results. | Nat Med | 2023 |
| 37126944 | Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. | J Clin Oncol | 2023 |
| 36625510 | Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I. | J Natl Cancer Inst | 2023 |
| 36720083 | Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. | J Clin Oncol | 2023 |
| 36774937 | The end of the beginning: progress and next steps in KRAS-mutant non-small-cell lung cancer. | Lancet | 2023 |
| 36900339 | Comparing Detection Schemes for Adversarial Images against Deep Learning Models for Cancer Imaging. | Cancers (Basel) | 2023 |
| 34740861 | Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. | J Thorac Oncol | 2022 |
| 35649657 | Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. | J Immunother Cancer | 2022 |
| 35581307 | Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer. | Lab Invest | 2022 |
| 35701637 | Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. | Nat Rev Drug Discov | 2022 |
| 35764237 | Programmed Death-Ligand 1 and Programmed Death-Ligand 2 mRNAs Measured Using Closed-System Quantitative Real-Time Polymerase Chain Reaction Are Associated With Outcome and High Negative Predictive Value in Immunotherapy-Treated NSCLC. | J Thorac Oncol | 2022 |
| 35793873 | Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer. | J Immunother Cancer | 2022 |
| 35640927 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. | J Immunother Cancer | 2022 |
| 35490853 | Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling. | J Thorac Oncol | 2022 |
| 35459795 | Development of an immunohistochemical assay for Siglec-15. | Lab Invest | 2022 |
| 35660136 | When immunotherapy meets surgery in non-small cell lung cancer. | Cancer Cell | 2022 |
| 35452273 | COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. | J Clin Oncol | 2022 |
| 35858709 | Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects. | J Immunother Cancer | 2022 |
| 35713632 | Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403). | Clin Cancer Res | 2022 |
| 36446042 | Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. | JCO Precis Oncol | 2022 |
| 36002182 | Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer. | J Immunother Cancer | 2022 |
| 36107783 | Future Directions in the Management of Non-Small Cell Lung Cancer Harboring Driver Mutations. | Oncology (Williston Park) | 2022 |
| 36175037 | Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). | J Immunother Cancer | 2022 |
| 36287033 | Electronic Nicotine Delivery Systems: An Updated Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology. | Clin Cancer Res | 2022 |
| 36287017 | Electronic Nicotine Delivery Systems: An Updated Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology. | J Clin Oncol | 2022 |
| 35012927 | Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial. | Clin Cancer Res | 2022 |
| 35247929 | RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition. | Clin Cancer Res | 2022 |
| 35176458 | ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. | Ann Oncol | 2022 |
| 35271304 | Using Adversarial Images to Assess the Robustness of Deep Learning Models Trained on Diagnostic Images in Oncology. | JCO Clin Cancer Inform | 2022 |
| 35142793 | Nivolumab Plus Ipilimumab for Previously Treated Stage IV Squamous Cell Lung Cancer-Reply. | JAMA Oncol | 2022 |
| 34753703 | EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. | Clin Lung Cancer | 2022 |
| 33148678 | Clearing the Haze: What Do We Still Need to Learn about Electronic Nicotine Delivery Systems? | Cancer Prev Res (Phila) | 2021 |
| 33596365 | Osimertinib in EGFR-Mutated Lung Cancer. Reply. | N Engl J Med | 2021 |
| 33596364 | Osimertinib in EGFR-Mutated Lung Cancer. | N Engl J Med | 2021 |
| 33788846 | Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection. | PLoS One | 2021 |
| 33567202 | Atezolizumab for PD-L1-Selected Patients with NSCLC. Reply. | N Engl J Med | 2021 |
| 33567201 | Atezolizumab for PD-L1-Selected Patients with NSCLC. | N Engl J Med | 2021 |
| 33567200 | Atezolizumab for PD-L1-Selected Patients with NSCLC. | N Engl J Med | 2021 |
| 33583720 | Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. | Clin Lung Cancer | 2021 |